Abstract | OBJECTIVE: To describe cases of lymphoma associated with anti-TNF therapy, identify risk factors, estimate the incidence and compare the risks for different anti-TNF agents. METHODS: A national prospective registry was designed (Research Axed on Tolerance of bIOtherapies; RATIO) to collect all cases of lymphoma in French patients receiving anti-TNF therapy from 2004 to 2006, whatever the indication. A case-control analysis was conducted including two controls treated with anti-TNF per case and an incidence study of lymphoma with the French population was used as the reference. RESULTS: 38 cases of lymphoma, 31 non-Hodgkin's lymphoma (NHL) (26 B cell and five T cell), five Hodgkin's lymphoma (HL) and two Hodgkin's-like lymphoma were collected. Epstein-Barr virus was detected in both of two Hodgkin's-like lymphoma, three of five HL and one NHL. Patients receiving adalimumab or infliximab had a higher risk than those treated with etanercept: standardised incidence ratio (SIR) 4.1 (2.3-7.1) and 3.6 (2.3-5.6) versus 0.9 (0.4-1.8). The exposure to adalimumab or infliximab versus etanercept was an independent risk factor for lymphoma in the case-control study: odds ratio 4.7 (1.3-17.7) and 4.1 (1.4-12.5), respectively. The sex and age-adjusted incidence rate of lymphoma was 42.1 per 100 000 patient-years. The SIR was 2.4 (95% CI 1.7 to 3.2). CONCLUSION: The two to threefold increased risk of lymphoma in patients receiving anti-TNF therapy is similar to that expected for such patients with severe inflammatory diseases. Some lymphomas associated with immunosuppression may occur, and the risk of lymphoma is higher with monoclonal-antibody therapy than with soluble-receptor therapy.
|
Authors | X Mariette, F Tubach, H Bagheri, M Bardet, J M Berthelot, P Gaudin, D Heresbach, A Martin, T Schaeverbeke, D Salmon, M Lemann, O Hermine, M Raphael, P Ravaud |
Journal | Annals of the rheumatic diseases
(Ann Rheum Dis)
Vol. 69
Issue 2
Pg. 400-8
(Feb 2010)
ISSN: 1468-2060 [Electronic] England |
PMID | 19828563
(Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antirheumatic Agents
- Immunosuppressive Agents
- Tumor Necrosis Factor-alpha
|
Topics |
- Aged
- Antirheumatic Agents
(adverse effects, therapeutic use)
- Arthritis
(drug therapy)
- Epidemiologic Methods
- Female
- France
(epidemiology)
- Humans
- Immunocompromised Host
- Immunosuppressive Agents
(adverse effects, therapeutic use)
- Lymphoma
(chemically induced, epidemiology, immunology)
- Male
- Middle Aged
- Registries
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
|